Reshaping retina treatment with faricimab

Charters,Lynda;

Reshaping retina treatment with faricimab

March 14, 2022

Lynda Charters

Publication

Article

Modern Retina Digital EditionModern Retina Spring 2022

Volume 2

Issue 1

The first FDA-approved bispecific antibody for the eye targets two leading causes of vision loss.

Reviewed by Charles Wykoff, MD, PhD.

Reshaping retina treatment with faricimab

The FDA’s approval of faricimab (Vabysmo; Genentech) ushers in a new era for retina specialists and their patients with the potential to have a triple effect: inhibition of the disease processes of wet age-related macular degeneration (AMD) and diabetic macular edema (DME), improvement of visual acuity, and reduction of patient treatment burden.

Faricimab, the only injectable treatment simultaneously approved by the FDA to treat both wet AMD and DME, facilitates flexible dosing regimens based on the patient’s anatomy and their visual outcomes.

“Vabysmo represents an important step forward for ophthalmology. It is the first bispecific antibody approved for the eye,” noted Charles Wykoff, MD, PhD, director of research at Retina Consultants of Texas in Houston and a faricimab phase 3 investigator. “With Vabysmo, we now have the opportunity to offer patients a medicine that could improve their vision and potentially lower the treatment burden with fewer injections over time.”

Ophthalmologists may begin prescribing faricimab to patients in the coming weeks.

The mechanism of faricimab

The beauty of the formulation lies in the drug’s dual activity.

“It does more than block a single cytokine,” Wykoff said. “The current VEGF agents such as bevacizumab [Avastin; Genentech], ranibizumab [Lucentis; Genentech], and aflibercept [Eyela, Regeneron Pharmaceuticals Inc.] block only the VEGF pathway. Vabysmo is unique in that in addition to blocking the same VEGF pathway, it also blocks a separate one, the angiopoietin-2 [Ang-2] pathway. With the neutralization of Ang-2, the tyrosine kinase receptor Tie-2 is activated.”

This scenario differs from the activity of the anti-VEGF therapies. When VEGF is inhibited, signaling through its receptors is decreased. The blocking of Ang-2 allows activation of a specific pathway moderated by Tie-2, resulting in a very different cellular response.

“The thought is that inhibiting both VEGF and Ang-2 is complementary and can achieve improved anatomic outcomes,” Wykoff said.

These disease pathways seem to work by destabilizing the blood vessels, which can result in the formation of new leaky blood vessels and increased ocular inflammation.

According to Wykoff, the process of inhibiting both pathways results in stabilization of the blood vessels and subsequent decreased leaking and inflammation.

The activity of these 2 pathways resulting from faricimab is responsible for the increased intervals between treatments in most study patients compared with patients receiving the anti-VEGF therapies. With the individualized dosing of patients cross 4 phase 3 trials, Wykoff pointed out that 50% of patients could go 4 months between treatments and about 75% could go 3 months or more between treatments.

Wykoff also noted that although not definitive at this point, faricimab appears to have increased durability.

FDA approval

The approval of faricimab was based on results from 4 randomly assigned, multicenter, double-masked, global phase 3 studies, all of which showed consistent beneficial treatment effects in patients with wet AMD and DME.^1,2 After patients received the first 4 monthly doses of faricimab, to be administered at up to 4-month intervals, the results were equal to those achieved with aflibercept administered every 2 months during the first treatment year.

Patients generally tolerated faricimab well. The most frequently seen adverse effect was conjunctival hemorrhage in 7% of patients. Patients treated monthly with faricimab and aflibercept did not show increased retinal toxicity.

In clinical practice, treatment with faricimab will consist of a series of 4 initial monthly injections, followed by a flexible treatment schedule from 1 to 4 months apart based on a physician’s evaluation of the patient’s anatomy and vision outcomes.

“The package insert is relatively inclusive,” Wykoff said. “When needed, patients can be treated on a monthly basis, and there certainly is the option for less frequent dosing. In most cases, physicians can use Vabysmo as required by the patients.”

TENAYA and LUCERNE trials

The TENAYA (NCT03823287) and LUCERNE (NCT03823300) studies included 1329 patients with wet AMD. The results of these trials showed average increases in the visual acuity of +5.8 and +6.6 letters, respectively, in patients treated with 6.0-mg doses of faricimab at the 1-year evaluation compared with +5.1 and +6.6 letters in patients treated with 2.0-mg doses of aflibercept.

Importantly, Wykoff noted that the results also highlighted the decreased treatment burden in patients who received faricimab: 46% in the TENAYA study and 45% in the LUCERNE study were treated every 4 months during the first year; another 34% and 33% of patients, respectively, were treated every 3 months. Those data indicated that 80% of patients did not require treatment for 3 months or more during the first year

The visual results showed that the central subfield thickness (CST) decreased comparably, as did the size and area of the choroidal neovascularization, along with the visual improvements.

“The visual benefits with Vabysmo given at up to 16-week intervals demonstrate its potential to meaningfully extend the time between treatments with sustained efficacy, thereby reducing treatment burden in patients with neovascular AMD,” according to investigators.

YOSEMITE and RHINE trials

In the YOSEMITE (NCT03622580) and RHINE (NCT03622580) studies that included 1891 patients with DME, the faricimab results achieved with the 6.0-mg doses were comparable with those achieved with the 2.0-mg doses of aflibercept, with average letter gains of +11.6 and +10.8 in the faricimab treat-and-extend arms, +10.7 and +11.8 letters in the 2-month arms, and +10.9 and +10.3 letters in the aflibercept arms, respectively.

Regarding the treatment burden, 53% of those in the faricimab TAE arm in the YOSEMITE study and 51% in the RHINE study were treated every 4 months during the first year; an additional 21% and 20%, respectively, were treated every 3 months. This again indicated most patients (70%) in the TAE faricimab arm required dosing after 3 months or more during the first year.

The CST decrease and resolution of intraretinal fluid that occurred throughout the first year favored faricimab versus aflibercept.

In addition to the treatment regimens described, another approved regimen for DME involves 6 monthly loading doses, followed by treatment every 2 months. Patients with wet AMD and DME also can undergo monthly treatments as needed, although the study investigators pointed out that additional efficacy was not observed with monthly dosing.

“Robust vision gains and anatomical improvements with Vabysmo were achieved with adjustable dosing up to every 16 weeks, demonstrating the potential for Vabysmo to extend the durability of treatments for patients with diabetic macular edema,” Wykoff noted.

Extension studies

Extension studies are underway: AVONELLE-X (NCT04777201), the extension study of TENAYA and LUCERNE, is evaluating the long-term safety and tolerability of faricimab in wet AMD. RHONE-X (NCT0443283), the extension study of the YOSEMITE and RHINE studies, is investigating the long-term safety and tolerability of faricimab for DME.

Investigators are also considering the potential benefits of faricimab for other retinal diseases. The COMINO (NCT04740931) and BALATON (NCT04740905) trials are evaluating the efficacy and safety of the drug in patients with macular edema subsequent to retinal vein occlusion.

“The most exciting consideration is that we now have a next-generation pharmacotherapy that achieves what we know to be important in the treatment process, namely, inhibition of VEGFA, that also blocks a new cytokine, Ang-2,” Wykoff concluded. “There is a tremendous amount of preclinical data and strong clinical rational implicating Ang-2 in the pathophysiology of exudative retinal diseases, including DME and neovascular AMD. We now have a molecule that can block both pathways. There is tremendous promise that patients can achieve optimal outcomes with fewer injections over time.”